List of insiders holdings for Spyre Therapeutics Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
# | Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
1 | Alspaugh Jonathan President and CFO | 2023-06-30 16:34:47 | 19,787,969 0 | 19,787,969 | Form 4 |
2 | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 2024-04-25 16:55:38 | 0 5,176,222 | 5,176,222 | Form 4 |
3 | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 2024-04-25 16:40:00 | 4,508,579 0 | 4,508,579 | Form 13D |
4 | Lilly Ventures Fund I LLC Shanafelt Armen Torres S. Edward 10% Owner | 2021-02-12 16:59:33 | 2,568,543 0 | 2,568,543 | Form 13G |
5 | Lawton Alison Frances Director | 2023-06-30 16:30:12 | 1,950,000 0 | 1,950,000 | Form 4 |
6 | Smith Hunter C Director | 2023-06-30 16:31:16 | 1,950,000 0 | 1,950,000 | Form 4 |
7 | Magovcevic-Liebisch Ivana Director | 2023-06-30 16:32:34 | 1,950,000 0 | 1,950,000 | Form 4 |
8 | Cox Russell J. Director | 2023-06-30 16:33:37 | 1,950,000 0 | 1,950,000 | Form 4 |
9 | Goldberg Jeff Marc President and CEO | 2022-12-01 20:47:37 | 1,884,838 0 | 1,884,838 | Form 4 |
10 | ORBIMED ADVISORS LLC OrbiMed Capital GP V LLC ISALY SAMUEL D 10% Owner | 2023-02-14 16:01:11 | 1,797,221 0 | 1,797,221 | Form 13G |
11 | LILLY ELI & CO Lilly Ventures Fund I LLC Shanafelt Armen 10% Owner | 2022-02-10 16:13:03 | 1,526,516 0 | 1,526,516 | Form 13G |
12 | Quinn Anthony G. President & CEO | 2022-03-18 06:46:58 | 550,540 266,295 | 816,835 | Form 4 |
13 | Novartis Bioventures Ltd NOVARTIS AG 10% Owner | 2020-01-30 16:12:04 | 617,769 0 | 617,769 | Form 13G |
14 | Neuman Linda L Chief Medical Officer | 2023-02-24 18:25:30 | 550,000 0 | 550,000 | Form 4 |
15 | Kastenmayer James Paul General Counsel | 2023-02-24 18:24:11 | 500,000 0 | 500,000 | Form 4 |
16 | Hanley Jr. Michael Conick Chief Business Officer | 2023-02-24 18:22:20 | 500,000 0 | 500,000 | Form 4 |
17 | Turtle Cameron Chief Executive Officer | 2025-01-17 16:35:13 | 370,000 0 | 370,000 | Form 4 |
18 | HENDERSON MICHAEL THOMAS Director | 2025-01-14 17:16:29 | 210,758 0 | 210,758 | Form 4 |
19 | Rojas-Caro Sandra Chief Medical Officer | 2016-05-19 16:37:04 | 200,000 0 | 200,000 | Form 4 |
20 | GEORGIOU GEORGE Director | 2018-08-15 16:40:25 | 192,528 0 | 192,528 | Form 4 |
21 | Lowe David George CEO and President | 2017-03-22 16:53:40 | 160,000 0 | 160,000 | Form 4 |
22 | Sloan Leslie Chief Operating Officer | 2022-08-25 19:36:17 | 130,000 0 | 130,000 | Form 4 |
23 | York Charles N II Chief Financial Officer and VP | 2020-02-19 17:15:29 | 126,000 0 | 126,000 | Form 4 |
24 | Burrows Scott L Chief Financial Officer | 2025-01-17 16:36:48 | 95,500 0 | 95,500 | Form 4 |
25 | Sloan Sheldon Chief Medical Officer | 2025-01-17 16:36:00 | 95,500 0 | 95,500 | Form 4 |
26 | King-Jones Heidy See Remarks | 2025-01-17 16:34:06 | 95,500 0 | 95,500 | Form 4 |
27 | Souza Marcio Director | 2022-08-25 19:37:05 | 90,000 0 | 90,000 | Form 4 |
28 | Schuchart Aaron Chief Business Officer | 2019-03-01 17:09:04 | 60,000 0 | 60,000 | Form 4 |
29 | Wooldridge James Chief Medical Officer | 2019-03-01 17:09:49 | 50,200 0 | 50,200 | Form 4 |
30 | Shanafelt Armen Director | 2022-06-09 21:22:33 | 43,000 0 | 43,000 | Form 4 |
31 | Mahatme Sandesh Director | 2022-06-09 21:18:44 | 43,000 0 | 43,000 | Form 4 |
32 | LAWLIS V BRYAN Director | 2022-06-09 21:15:38 | 43,000 0 | 43,000 | Form 4 |
33 | McKenna Mark C. Director | 2024-02-05 17:29:40 | 40,000 0 | 40,000 | Form 4 |
34 | Hebel Henry VP, Product Development | 2017-03-22 16:52:59 | 38,200 0 | 38,200 | Form 4 |
35 | Weber Steven VP, Controller&Princ Acctg Off | 2022-02-22 16:55:42 | 30,000 0 | 30,000 | Form 4 |
36 | Bruhn Suzanne Louise Director | 2020-06-10 16:21:57 | 28,100 0 | 28,100 | Form 4 |
37 | Albers Jeffrey W. Director | 2024-11-08 16:53:52 | 0 27,360 | 27,360 | Form 4 |
38 | Rao Madduri Ravin Chief Medical Officer | 2020-02-19 17:14:05 | 25,000 0 | 25,000 | Form 4 |
39 | TYLER JOSEPH E VP, Manufacturing | 2017-08-24 18:03:31 | 25,000 0 | 25,000 | Form 4 |
40 | Rowlinson Scott W VP, Research | 2017-08-24 18:02:15 | 25,000 0 | 25,000 | Form 4 |
41 | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director | 2024-05-16 16:10:28 | 0 22,646 | 22,646 | Form 4 |
42 | Milligan Sandra Director | 2024-05-16 16:10:27 | 21,980 0 | 21,980 | Form 4 |
43 | Stelzer Laurie Director | 2024-05-16 16:10:16 | 11,323 0 | 11,323 | Form 4 |
44 | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director | 2024-02-14 16:21:51 | 0 0 | 0 | Form 13G |
45 | Brownstein Sara Director | 2021-02-25 19:30:36 | 0 0 | 0 | Form 3 |